Úloha molekulárnej biológie pri diagnostike a monitoringu karcinómu prostaty

English version

Autoři: A. Zummerová ¹; D. Böhmer ²; J. Fillo ³; Ľ. Danihel ⁴; V. Repiská ²
Působiště autorů: Department of Pathology and Forensic medicine, Health Care Surveillance Authority, Bratislava, Slovakia ¹; Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia ²; Department of Urology, Faculty Hospital, Bratislava, Slovakia ³; Department of Pathology, Faculty of Medicine, Comenius University, Bratislava, Slovakia ⁴
Vyšlo v časopise: Čes.-slov. Patol., 46, 2010, No. 4, p. 95-97
Kategorie: Vyzvaný článek

Souhrn

Štúdium molekulových markerov v rôznych neopláziách ako aj pri karcinóme prostaty je založené na analýze génov, ktoré sa spolupodieľajú na vzniku karcinómu. Boli sledované mutácie, amplifikácie a iné zmeny týchto génov alebo ich produktov, ktoré sú porovnávané s tradičnými prognostickými markermi. Tieto gény možno označiť ako onkogény, tumor supresorové gény alebo gény s inými významnými bunkovými funkciami. Štúdie karcinómu prostaty sú často limitované heterogenitou tohto nádoru. V predloženej práci predkladáme prehľad niektorých najčastejších diagnostických a prognostických molekulovo biologických markerov vyšetrovaných v súvislosti s karcinómom prostaty.

Kľúčové slová:
karcinóm prostaty – molekulárna biológia – molekulárne markery

Zdroje

1. Alcaide, J., Pineiro, L.M.: Pathological and molecular aspects of prostate cancer. The Lancet, 361, 2007, s. 955–964.

2. Altimari, A., Grigioni, A., Benedettini, E. et al.: Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am. J. Clin. Pathol., 129, 2008, s. 756–62.

3. Arap, M.A.: Molecular biology in prostate cancer. Arch. Esp. Urol., 63, 2010, s. 1-9.

4. Catalona, W.J., Loeb, S.: Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values. J. Natl. Compr. Canc. Netw., 8, 2010, s. 265–270.

5. Chang, G.T., Steenbeek, M., Schippers, E. et al.: Characterization of a zinc-finger protein and its association with apoptosis in prostate pancer cells. JNCI Journal of the National Cancer Institute, 92, 2000, s. 1414–1421.

6. Ghossein, R.A., Scher, H.I., Gerald, W.L. et al.: Detecting of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol., 13, 1995, s. 1195–1200.

7. Grasso, Y.Z., Gupta, M.K., Levin, H.S. et al.: Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with Pathological Stage, Cancer Research, 58, 1998, s. 1456–1459.

8. Huang, Ch., Brassil, D., Rozzell, M., et al.: Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate, 23, 1993, s. 201–212.

9. Katz, A.E., Olsson, C.A., Raffo, A.J. et al.: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology, 43, 1994, s. 765–775.

10. Klein, K.A., Reiter, R.E., Redula, J. et al.: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Medicine, 3, 1997, s. 402–408.

11. Kliment, J., Horňák, M. et al.: Karcinóm prostaty. Martin: Vydavateľstvo Osveta, 1999, s. 25.

12. Leman, E.S, Canon, G., Trock, B: EPCA-2: a highly specific serum marker for prostate cancer. Urology, 69, 2007, s. 714.

13. Linja, M., Savinainen, K., Saramäki, O. et al..: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research, 61, 2001, s. 3550–3555.

14. Loric, S., Dumas, F., Eschwege, P. et al.: Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. , 41, 1995, s. 1698–1704.

15. Mackinnon, A.C., Yan, B.C., Joseph, L.J. et al.: Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch. Pathol. Lab. Med., 133, 2009, s. 1033–40.

16. Magee, J., Araki, T., Patil, S. et al.: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Research, 61, 2001, s. 5692–5696.

17. Moreno, J.G., Croce, C.M., Rischer, R. et al: Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Research, 52, 1992, s. 6110–6112.

18. Repiská, V., Mikloši, M., Zummerová, A. et al.: Detection of circulating tumor cells in patients with prostate cancer. Biologia, 60, 2005, s. 703–709.

19. Thompson, I.M., Pauler, D.K., Goodman, P.J. et al: Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter.

20. Tomlins, S., Rhodes, D., Perner, S. et al.: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 2005, s. 664–648.

21. Vessella, R.L., Riley, D.E., Blouke, K.A. et al.: A sensitive method for detection of a prostate tumor cell marker using the polymerase chain reaction. J. Urol., 2, 1992, s. 147–148.

22. Whang, Y., Wu, X., Suzuki, H. et al.: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Nad. Acad. Sci., 95, 1998, s. 5246–5250.